

Maria C Carrillo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8644517/publications.pdf>

Version: 2024-02-01

66
papers

25,151
citations

126907

33
h-index

138484

58
g-index

66
all docs

66
docs citations

66
times ranked

24927
citing authors

#	ARTICLE	IF	CITATIONS
1	The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging and Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2011, 7, 263-269.	0.8	12,681
2	NIA and AHA Research Framework: Toward a biological definition of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 535-562.	0.8	5,861
3	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. <i>Alzheimer's and Dementia</i> , 2016, 12, 292-323.	0.8	1,318
4	Summary of the evidence on modifiable risk factors for cognitive decline and dementia: A population-based perspective. <i>Alzheimer's and Dementia</i> , 2015, 11, 718-726.	0.8	1,187
5	Vascular contributions to cognitive impairment and dementia including Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 710-717.	0.8	461
6	Consensus classification of posterior cortical atrophy. <i>Alzheimer's and Dementia</i> , 2017, 13, 870-884.	0.8	423
7	Research priorities to reduce the global burden of dementia by 2025. <i>Lancet Neurology</i> , The, 2016, 15, 1285-1294.	10.2	284
8	Worldwide FINGERS Network: A global approach to risk reduction and prevention of dementia. <i>Alzheimer's and Dementia</i> , 2020, 16, 1078-1094.	0.8	257
9	Down syndrome and Alzheimer's disease: Common pathways, common goals. <i>Alzheimer's and Dementia</i> , 2015, 11, 700-709.	0.8	218
10	Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research. <i>Alzheimer's and Dementia</i> , 2015, 11, 549-560.	0.8	205
11	Sex biology contributions to vulnerability to Alzheimer's disease: A think tank convened by the Women's Alzheimer's Research Initiative. <i>Alzheimer's and Dementia</i> , 2016, 12, 1186-1196.	0.8	180
12	The roles of inflammation and immune mechanisms in Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2016, 2, 99-109.	3.7	161
13	Developing novel blood-based biomarkers for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, 109-114.	0.8	138
14	Tau: From research to clinical development. <i>Alzheimer's and Dementia</i> , 2016, 12, 1033-1039.	0.8	117
15	Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: An update from the Alzheimer's Association Global Biomarkers Consortium. <i>Alzheimer's and Dementia</i> , 2013, 9, 137-140.	0.8	105
16	Can we prevent Alzheimer's disease? Secondary "prevention" trials in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2013, 9, 123.	0.8	100
17	Multiple comorbid neuropathologies in the setting of Alzheimer's disease neuropathology and implications for drug development. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 83-91.	3.7	94
18	Retinal imaging in Alzheimer's and neurodegenerative diseases. <i>Alzheimer's and Dementia</i> , 2021, 17, 103-111.	0.8	89

#	ARTICLE	IF	CITATIONS
19	Alzheimer's disease: The next frontierâ€”Special Report 2017. <i>Alzheimer's and Dementia</i> , 2017, 13, 374-380.	0.8	88
20	Worldwide Alzheimer's Disease Neuroimaging Initiative. <i>Alzheimer's and Dementia</i> , 2012, 8, 337-342.	0.8	84
21	Revolutionizing Alzheimer's disease and clinical trials through biomarkers. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 412-419.	2.4	80
22	CAPâ€”advancing the evaluation of preclinical Alzheimer disease treatments. <i>Nature Reviews Neurology</i> , 2016, 12, 56-61.	10.1	80
23	The case for low-level BACE1 inhibition for the prevention of Alzheimer disease. <i>Nature Reviews Neurology</i> , 2021, 17, 703-714.	10.1	65
24	2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease. , 2014, 10, S430-S452.		64
25	Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: Recommendations of an expert panel. <i>Alzheimer's and Dementia</i> , 2021, 17, 1528-1553.	0.8	64
26	Alzheimer's Disease prevalence, costs, and prevention for military personnel and veterans. <i>Alzheimer's and Dementia</i> , 2014, 10, S105-10.	0.8	56
27	Association Between Ambient Air Pollution and Amyloid Positron Emission Tomography Positivity in Older Adults With Cognitive Impairment. <i>JAMA Neurology</i> , 2021, 78, 197.	9.0	54
28	Further understanding the connection between Alzheimer's disease and Down syndrome. <i>Alzheimer's and Dementia</i> , 2020, 16, 1065-1077.	0.8	52
29	Round robin test on quantification of amyloidâ€” β 1â€”42 in cerebrospinal fluid by mass spectrometry. <i>Alzheimer's and Dementia</i> , 2016, 12, 55-59.	0.8	46
30	The Worldwide Alzheimer's Disease Neuroimaging Initiative: An update. <i>Alzheimer's and Dementia</i> , 2015, 11, 850-859.	0.8	43
31	Revisiting the framework of the National Institute on Agingâ€”Alzheimer's Association diagnostic criteria. <i>Alzheimer's and Dementia</i> , 2013, 9, 594-601.	0.8	42
32	Ethical challenges in preclinical Alzheimer's disease observational studies and trials: Results of the Barcelona summit. <i>Alzheimer's and Dementia</i> , 2016, 12, 614-622.	0.8	42
33	Challenges, solutions, and recommendations for Alzheimer's disease combination therapy. , 2016, 12, 623-630.		39
34	The biomarker-based diagnosis of Alzheimer's disease. 1â€”ethical and societal issues. <i>Neurobiology of Aging</i> , 2017, 52, 132-140.	3.1	39
35	Randomized controlled trials in mild cognitive impairment. <i>Neurology</i> , 2017, 88, 1751-1758.	1.1	35
36	Exploring the nexus of Alzheimer's disease and related dementias with cancer and cancer therapies: A convening of the Alzheimer's Association & Alzheimer's Drug Discovery Foundation. <i>Alzheimer's and Dementia</i> , 2017, 13, 267-273.	0.8	35

#	ARTICLE	IF	CITATIONS
37	Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline. <i>Journal of Alzheimer's Disease</i> , 2015, 48, S171-S191.	2.6	34
38	The Longitudinal Early-onset Alzheimer's Disease Study (LEADS): Framework and methodology. <i>Alzheimer's and Dementia</i> , 2021, 17, 2043-2055.	0.8	34
39	Collaboration for Alzheimer's Prevention: Principles to guide data and sample sharing in preclinical Alzheimer's disease trials. <i>Alzheimer's and Dementia</i> , 2016, 12, 631-632.	0.8	26
40	Testing and disclosures related to amyloid imaging and Alzheimer's disease: Common questions and fact sheet summary. <i>Alzheimer's and Dementia</i> , 2016, 12, 510-515.	0.8	23
41	Military-related risk factors for dementia. <i>Alzheimer's and Dementia</i> , 2018, 14, 1651-1662.	0.8	18
42	rPOP: Robust PET-only processing of community acquired heterogeneous amyloid-PET data. <i>NeuroImage</i> , 2022, 246, 118775.	4.2	17
43	Alzheimer's disease research in the context of the national plan to address Alzheimer's disease. <i>Molecular Aspects of Medicine</i> , 2015, 43-44, 16-24.	6.4	14
44	Working Group Recommendations for the Practice of Teleneuropsychology in Latin America. <i>Archives of Clinical Neuropsychology</i> , 2022, 37, 553-567.	0.5	12
45	Perspective: The Alzheimer's Disease Neuroimaging Initiative and the role and contributions of the Private Partner Scientific Board (PPSB). <i>Alzheimer's and Dementia</i> , 2015, 11, 840-849.	0.8	10
46	Alzheimer's disease public-private partnerships: Update 2014. <i>Alzheimer's and Dementia</i> , 2014, 10, 873-880.	0.8	9
47	EEG measures for clinical research in major vascular cognitive impairment: recommendations by an expert panel. <i>Neurobiology of Aging</i> , 2021, 103, 78-97.	3.1	9
48	Alzheimer's disease research in Ibero America. <i>Alzheimer's and Dementia</i> , 2016, 12, 749-754.	0.8	7
49	National Institute on Aging "Alzheimer's Association Research Framework lays the groundwork for deeper understanding of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 261-262.	0.8	7
50	Justifying reimbursement for Alzheimer's diagnostics and treatments: Seeking alignment on evidence. , 2014, 10, 503-508.		6
51	Is cognitive decline measurable in preclinical Alzheimer's disease?. <i>Alzheimer's and Dementia</i> , 2017, 13, 322-323.	0.8	6
52	Potential roles of digital technologies in clinical trials. <i>Alzheimer's and Dementia</i> , 2017, 13, 1075-1076.	0.8	6
53	Patient and Caregiver Assessment of the Benefits From the Clinical Use of Amyloid PET Imaging. <i>Alzheimer Disease and Associated Disorders</i> , 2018, 32, 35-42.	1.3	5
54	The pathway to secondary prevention of Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12069.	3.7	5

#	ARTICLE	IF	CITATIONS
55	Commentary: Global Alzheimer's disease and Alzheimer's disease related dementia research funding organizations support and engage the research community throughout the COVID-19 pandemic. <i>Alzheimer's and Dementia</i> , 2022, 18, 1067-1070.	0.8	4
56	Alzheimer's disease public-private partnerships: Update 2017. , 2018, 14, 522-531.		3
57	How Should Cognitive Impairment Be Recognized?. <i>Journal of the American Medical Directors Association</i> , 2015, 16, 813-814.	2.5	2
58	Considering new treatment paradigms for neuropsychiatric symptoms of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2016, 12, 1031-1032.	0.8	2
59	Clinical meaningfulness addressed at Alzheimer's Association Research Roundtable. <i>Alzheimer's and Dementia</i> , 2020, 16, 814-814.	0.8	2
60	Letter to the Editor re: Nexus of Cancer & Alzheimer's. <i>Alzheimer's and Dementia</i> , 2017, 13, 722-722.	0.8	1
61	Combination therapy for Alzheimer's disease: Are we ready?. <i>Alzheimer's and Dementia</i> , 2018, 14, 1232-1233.	0.8	1
62	Lifestyle and its Potential to Preserve Cognitive Function and Reduce the Risk of Dementia. <i>US Neurology</i> , 2018, 14, 11.	0.2	1
63	Perspective from the Alzheimer's Association: Neuroimaging Professional Interest Area of ISTAART continues impact on the field. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 5, 1-2.	2.4	0
64	AAIC Satellite Symposium explores Alzheimer's disease research in South Asia. , 2019, 15, 726-727.		0
65	Targeting Alzheimer's Disease in the Preclinical Stage. , 2019, 15, 602-603.		0
66	Scientific Advising and Reviewing: On strengthening the bond between the Alzheimer's Association and the scientific community. <i>Alzheimer's and Dementia</i> , 2020, 16, 1095-1098.	0.8	0